Literature DB >> 29232600

A retrospective review of phyllodes tumours of the breast: A single institution experience.

Vithusha Ganesh1, Leah Drost1, Justin Lee1, Bo Angela Wan1, Liying Zhang1, Eileen Rakovitch1, Danny Vesprini1, Elzbieta Slodkowska1, K Liang Zeng1, Philomena Sousa1, Caitlin Yee1, Henry Lam1, Edward Chow2.   

Abstract

BACKGROUND: Phyllodes tumours are rare and histologically diverse, posing challenges in prognosis and treatment. Due to their rarity, they have seldom been studied.
PURPOSE: The purpose was to investigate clinical practices in the management of phyllodes tumours, as well as patient outcomes to contribute to the limited body of knowledge surrounding these tumours.
METHODS: A retrospective review was conducted on all patients with phyllodes tumours at a single institution. Descriptive analyses were conducted on demographic, disease and treatment (breast-conserving surgery, mastectomy, surgical re-excision, adjuvant/palliative radiation, palliative chemotherapy) information. Overall and disease-free survivals were analyzed, and the cumulative incidence of recurrence and metastases was compared.
RESULTS: 79 patients with phyllodes tumours of the breast were included in the study. Tumours were classified as malignant, borderline, or benign in 67.1%, 21.5%, and 11.4% of patients, respectively. There were no statistically significant differences in overall or disease-free survival between patients with benign, borderline or malignant disease. Only patients with malignant disease developed recurrence or metastases. Those with malignant disease who received mastectomies had a lower 10-year cumulative incidence of recurrence; however this was not statistically significant (p = 0.69). All patients had negative surgical margins due to a re-excision or mastectomy following margin-positive breast conserving surgery. Of all risk factors assessed, necrosis was significantly associated with increased incidence of recurrence (local or distant) in patients with malignant disease (p = 0.03).
CONCLUSION: The presence of tumour necrosis is a significant negative prognostic factor. Breast-conserving surgery may be adequate in providing local control, given negative surgical margins.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast tumor; Phyllodes tumor; Prognosis; Retrospective; Treatment

Mesh:

Year:  2017        PMID: 29232600     DOI: 10.1016/j.breast.2017.12.008

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  5 in total

1.  Surgical margins for borderline and malignant phyllodes tumours.

Authors:  A Thind; B Patel; K Thind; J Isherwood; B Phillips; K Dhaliwal; D D Remoundos
Journal:  Ann R Coll Surg Engl       Date:  2020-01-10       Impact factor: 1.891

2.  Retrospective study of malignant phyllodes tumors of the breast: Younger age, prior fibroadenoma surgery, malignant heterologous elements and surgical margins may predict recurrence.

Authors:  Yang Li; Yixuan Song; Ronggang Lang; Lu Shi; Shuang Gao; Hong Liu; Ping Wang
Journal:  Breast       Date:  2021-03-17       Impact factor: 4.380

Review 3.  Phyllodes Tumors: A Scoping Review of the Literature.

Authors:  Jessica Bogach; Saad Shakeel; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

4.  Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases.

Authors:  Elisabetta Di Liso; Michele Bottosso; Marcello Lo Mele; Vassilena Tsvetkova; Maria Vittoria Dieci; Federica Miglietta; Cristina Falci; Giovanni Faggioni; Giulia Tasca; Carlo Alberto Giorgi; Tommaso Giarratano; Eleonora Mioranza; Silvia Michieletto; Tania Saibene; Angelo Paolo Dei Tos; PierFranco Conte; Valentina Guarneri
Journal:  ESMO Open       Date:  2020-10

5.  The treatment process of an extremely rare giant borderline phyllodes tumor of breast: case report and literature review.

Authors:  Qing Wang; Kai Zheng; Lei Zhang; Mingjian Tan; Hongwan Li; Hengyu Zhang; Dong Chen; Zhilin Li; Zhirui Chuan; Xi Wang; Yuanxiao Wang; Lei Zhe; Lijuan Liu; Dequan Liu; Rong Guo; Shicong Tang
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.